Ebola Treatment Shown to Work on Infected Monkeys

Global Security Newswire Staff
See more stories about...
Global Security Newswire Staff
Aug. 22, 2013, 9:02 a.m.

A new Ebola drug grown from spe­cial to­bacco plants has been shown to cure mon­keys that were already dis­play­ing signs of in­fec­tion by the vir­al hem­or­rhagic fever, the Los Angeles Times re­por­ted on Wed­nes­day.

Oth­er Ebola coun­ter­meas­ures have been shown to work on in­fec­ted an­im­als be­fore they start dis­play­ing symp­toms of the highly vir­u­lent and leth­al dis­ease. However, this is the first time a drug has demon­strated any ef­fect­ive­ness after signs of the vir­us have mani­fes­ted. That is re­garded as a cru­cial cap­ab­il­ity in the event of a real-life dis­ease epi­dem­ic, ac­cord­ing to vir­o­lo­gist Gene Olinger, who works at the Army Med­ic­al Re­search In­sti­tute of In­fec­tious Dis­eases at Fort De­t­rick, Md.

“We’ve pushed the op­por­tun­ity to treat people to the point where they walk in and say, ‘I have a fever,’” said Olinger, co-au­thor of a re­port on the new Ebola drug pub­lished by the Sci­ence Trans­la­tion­al Medi­cine journ­al on Wed­nes­day. “A lot of folks in the field would have thought pro­tect­ing an an­im­al at the time of fever and viremia is too late to have a clin­ic­al be­ne­fit.”

Ebola is one of the most deadly and con­ta­gious dis­eases known to ex­ist in nature. The lack of ad­equate vac­cines and an­ti­dotes for the dis­ease have made it a ser­i­ous worry for biode­fense spe­cial­ists con­cerned about its pos­sible ap­plic­a­tions as a bio­lo­gic­al weapon.

In the re­cent study, sev­en in­fec­ted rhesus mon­keys were ad­min­istered the ex­per­i­ment­al treat­ment MB-003 through their veins once every three days. Three of the mon­keys did not die, res­ult­ing in a stat­ist­ic­ally not­able suc­cess rate of 43 per­cent.

Fort De­t­rick sci­ent­ist and lead study au­thor James Pet­titt said it is prob­able that in a real-life out­break, the drug would be ad­min­istered at a high­er dosage and with great­er fre­quency.

“We think we’ll get bet­ter res­ults,” the re­search­er said.

Grow­ing the drug from spe­cially de­veloped to­bacco leaves is not only less costly than con­ven­tion­al cell-based meth­ods, but also al­lows for large batches of the drug to be pro­duced on fairly short, weeklong sched­ules, ac­cord­ing to the Times art­icle.

Olinger said fur­ther meas­ures will be taken to im­prove MB-003 by adding to it more Ebola an­ti­bod­ies that were dis­covered by a dif­fer­ent group of re­search­ers.

What We're Following See More »
WEST WING REDUX
Allison Janney Takes to the Real White House Podium
2 hours ago
WHY WE CARE

Carolyn Kaster/AP

STAFF PICKS
When It Comes to Mining Asteroids, Technology Is Only the First Problem
2 hours ago
WHY WE CARE

Foreign Policy takes a look at the future of mining the estimated "100,000 near-Earth objects—including asteroids and comets—in the neighborhood of our planet. Some of these NEOs, as they’re called, are small. Others are substantial and potentially packed full of water and various important minerals, such as nickel, cobalt, and iron. One day, advocates believe, those objects will be tapped by variations on the equipment used in the coal mines of Kentucky or in the diamond mines of Africa. And for immense gain: According to industry experts, the contents of a single asteroid could be worth trillions of dollars." But the technology to get us there is only the first step. Experts say "a multinational body might emerge" to manage rights to NEOs, as well as a body of law, including an international court.

Source:
STAFF PICKS
Obama Reflects on His Economic Record
3 hours ago
WHY WE CARE

Not to be outdone by Jeffrey Goldberg's recent piece in The Atlantic about President Obama's foreign policy, the New York Times Magazine checks in with a longread on the president's economic legacy. In it, Obama is cognizant that the economic reality--73 straight months of growth--isn't matched by public perceptions. Some of that, he says, is due to a constant drumbeat from the right that "that denies any progress." But he also accepts some blame himself. “I mean, the truth of the matter is that if we had been able to more effectively communicate all the steps we had taken to the swing voter,” he said, “then we might have maintained a majority in the House or the Senate.”

Source:
STAFF PICKS
Reagan Families, Allies Lash Out at Will Ferrell
4 hours ago
WHY WE CARE

Ronald Reagan's children and political allies took to the media and Twitter this week to chide funnyman Will Ferrell for his plans to play a dementia-addled Reagan in his second term in a new comedy entitled Reagan. In an open letter, Reagan's daughter Patti Davis tells Ferrell, who's also a producer on the movie, “Perhaps for your comedy you would like to visit some dementia facilities. I have—I didn’t find anything comedic there, and my hope would be that if you’re a decent human being, you wouldn’t either.” Michael Reagan, the president's son, tweeted, "What an Outrag....Alzheimers is not joke...It kills..You should be ashamed all of you." And former Rep. Joe Walsh called it an example of "Hollywood taking a shot at conservatives again."

Source:
PEAK CONFIDENCE
Clinton No Longer Running Primary Ads
7 hours ago
WHY WE CARE

In a sign that she’s ready to put a longer-than-ex­pec­ted primary battle be­hind her, former Sec­ret­ary of State Hil­lary Clin­ton (D) is no longer go­ing on the air in up­com­ing primary states. “Team Clin­ton hasn’t spent a single cent in … Cali­for­nia, In­di­ana, Ken­tucky, Ore­gon and West Vir­gin­ia, while” Sen. Bernie Sanders’ (I-VT) “cam­paign has spent a little more than $1 mil­lion in those same states.” Meanwhile, Sen. Jeff Merkley (D-OR), Sanders’ "lone back­er in the Sen­ate, said the can­did­ate should end his pres­id­en­tial cam­paign if he’s los­ing to Hil­lary Clin­ton after the primary sea­son con­cludes in June, break­ing sharply with the can­did­ate who is vow­ing to take his in­sur­gent bid to the party con­ven­tion in Phil­adelphia.”

Source:
×